Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ

Breast Cancer Research

Volumn 16, Issue 1, 2014, Pages

  Estévez, Laura G ^a   Suarez Gauthier, Ana ^a   García, Elena ^b   Miró, Cristina ^a   Calvo, Isabel ^a   Fernández Abad, María ^a   Herrero, Mercedes ^a   Marcos, Manuel ^a   Márquez, Cristina ^a   Ríos, Fernando Lopez ^a   Perea, Sofía ^a   Hidalgo, Manuel ^a,c  

^a Centro Integral Oncologico Clara Campal   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^c Structural Biology and Biocomputing Programme   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P27; RAS PROTEIN;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; ENZYME PHOSPHORYLATION; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MASTECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); PREOPERATIVE PERIOD; PROSPECTIVE STUDY; PROTEIN EXPRESSION; RASH; SIGNAL TRANSDUCTION; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84926475262     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3695     Document Type: Article

References (34)

1. Winchester DJ, Menk HR, Winchester DP: National treatment trends for ductal carcinoma in situ of the breast. Arch Surg 1997, 132:660-665.
2. Ben-David MA, Sturtz DE, Griffith KA, Douglas KR, Hayman JA, Lichter AS, Pierce LJ: Long-term results of conservative surgery and radiotherapy for ductal carcinoma in situ using lung density correction: the University of Michigan experience. Breast J 2007, 13:392-400.
3. Hieken TJ, Cheregi J, Farolan M, Kim J, Velasco JM: Predicting relapse in ductal carcinoma in situ patients: an analysis of biologic markers with long-term follow-up. Am J Surg 2007, 194:504-506.
4. Patani N, Cutuli B, Mokbel K: Current management of DCIS: a review. Breast Cancer Res Treat 2008, 111:1-10.
5. Vazquez B, Rousseau D, Hurd TC: Surgical management of breast cancer. Semin Oncol 2007, 34:234-240.
6. Kuhl CK, Schrading S, Bieling HB, Wardelmann E, Leutner CC, Koenig R, Khun W, Schild HH: MRI for diagnosis of pure ductal carcinoma in situ: a prospective observational study. Lancet 2007, 370:485-492.
7. Estévez LG, Alvarez I, Seguí MA, Muñoz M, Margelí M, Miró C, Rubio C, Lluch A, Tusquets I: Current perspectives of ductal carcinoma in situ. Cancer Treat Rev 2010, 36:507-517.
8. Hoque A, Sneige N, Sahin AA: Her-2/neu gene amplification in ductal carcinoma in situ of the breast. Cancer Epidemiol Biomarkers Prev 2002, 11:587-590.
9. Lindemann K, Resau J, Nahrig J, Kort E, Leeser B, Annecke K, Welk A, Schäefer J, Vande Woude GF, Lengyel E, Harbeck: Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue. Histopathology 2007, 51:54-62.
10. Steinman S, Wang J, Bourne P, Yang Q, Tang P: Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast. Ann Clin Lab Sci 2007, 37:127-134.
11. Howe LR, Brown PH: Targeting the HER/EGFR/ErbB family to prevent breast cancer. Cancer Prev Res (Phila) 2011, 4:1149-1157.
12. Dillon RL, White DE, Muller WJ: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene 2007, 26:1338-1345.
13. Tevaarwerk AJ, Kolesar JM: Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009, 31:2332-2348.
14. Giampaglia M, Chiuri VE, Tinelli A, De Laurentiis M, Silvestris N, Lorusso V: Lapatinib in breast cancer: clinical experiences and future perspectives. Cancer Treat Rev 2010, 36:S72-S79.
15. Moy B, Kirkpatrick P, Kar S, Goss P: Lapatinib. Nat Rev Drug Discov 2007, 6:431-432.
16. Geyer CE, Forster J, Lindquist D, Chan S, Romieu G, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D: Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
17. Konecny GE, Pegram MD, Venkatesan N, Finn R, Yand G, Rahmeh M, Untch M, Rusnak DW, Spehar G, Mullin RJ, Keith BR, Gilmer TM, Berger M, Podratz KC, Slamon DJ: Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res 2006, 66:1630-1639.
18. Xia W, Bisi J, Strum J, Liu L, Carrick K, Graham KM, Treece AL, Hardwicke MA, Dush M, Liao Q, Westlund RE, Zhao S, Bacus S, Spector NL: Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers. Cancer Res 2006, 66:1640-1647.
19. Moy B, Goss PE: Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007, 12:756-765.
20. WolffAC, Hammond ME, Schwartz JN, WolffAC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dwosett M, Fitzgibbons PL, Hann WM, Langer A, Mc Shane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology; College of American of Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
21. Morakkabati-Spitz N, Leutner C, Schild HH, Träber F, Kuhl CK: Diagnostic usefulness of segmental and linear enhancement in dynamic breast MRI. Eur Radiol 2005, 15:2010-2017.
22. Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, Janne PA, Johnson BE, Van den Abbeele AD: New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. AJR Am J Roentgenol 2010, 195:W221-W228.
23. Angulo B, Suarez-Gauthier A, Lopez-Rios F, Medina PP, Conde E, Tang M, Soler G, Lopez-Encuentra A, Cigudosa JC, Sanchez-Cespedes M: Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 2008, 214:347-356.
24. Loo DT: In situ detection of apoptosis by the TUNEL assay: an overview of techniques. Methods Mol Biol 2011, 682:3-13.
25. Rexer BN, Arteaga CL: Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 2012, 17:1-16.
26. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans E, Veelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R: A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
27. Dave B, Migliaccio I, Gutierrez MC, Wu MF, Chamness GC, Wong H, Narasanna A, Chakrabarty A, Hilsenbeck SG, Huang J, Rimawi M, SchiffR, Arteaga C, Osborne CK, Chang JC: Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to Trastuzumab or Lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 2011, 29:166-173.
28. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi K, Meric-Bernstam F, Hunt KK, Symmans WF: Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 2011, 117:39-47.
29. Boughey JC, González RJ, Bonner E, Kuerer HM: Current treatment and clinical trial developments for ductal carcinoma in situ of the breast. Oncologist 2007, 12:1276-1287.
30. Boyages J, Delaney G, Taylor R: Predictors of local recurrence after treatment of ductal carcinoma in situ: A meta-analysis. Cancer 1999, 85:616-628.
31. Mohsin SK, Weiss HL, Gutierrez MC, Chamness GD, SchiffR, Digiovanna MP, Wand CX, Hilsenbeck SG, Osborne CK, Allred CD, Elledge R, Chang JC: Neoadjuvant trastuzumab induces apoptosis in primary breast cancers. J Clin Oncol 2005, 23:2460-2468.
32. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'Hern R, Nerurkar A, Osin P, Smith IE, Dowsett M: Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010, 12:R76.
33. Garrett JT, Olivares MG, Rinehart C, Granja-Ingram ND, Sánchez V, Chakrabarty A, Dave B, Cook RS, Pao W, McKinely E, Manning HC, Chang J, Arteaga CL: Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase. Proc Natl Acad Sci USA 2011, 108:5021-5026.
34. Bose S, Chandran S, Mirocha JM, Bose N: The Akt pathway in human breast cancer: a tissue-array-based analysis. Mod Pathol 2006, 19:238-245.